New
Predictive Oncology
The AI engine Fit Assessment
BetaThe company delivers pharma-targeted technology solutions (AI-driven oncology data analysis, drug discovery and development platforms) and collaborates with pharmaceutical companies.
Blurb
Predictive Oncology is working with the pharmaceutical, diagnostic, and biotech industries to develop customizable assessment methods.
HQ Location
Eagan (United States)
Founded
2002
Employees
11 - 50
Total funding raised
$437.83M
Funding Status
Post-IPO Equity, $343.50M, September 29, 2025
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.
Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies.